Last updated: February 21, 2026
What is the scope of patent MX2008013407?
Patent MX2008013407 pertains to a pharmaceutical invention filed in Mexico, with a primary focus on a specific drug formulation or method. Its scope encompasses claims related to the composition, method of production, and potential uses of a particular chemical entity or combination.
The patent covers:
- A novel drug composition involving specific active ingredients.
- Processes for manufacturing said composition.
- Methods of use targeting particular indications or patient populations.
The claims are structured to protect both the chemical entity and its application in treatment protocols, including dosage forms, excipient combinations, or delivery mechanisms.
What are the main claims made in MX2008013407?
The patent contains multiple claims categorized as independent and dependent:
Independent Claims:
- Claim 1: Defines a pharmaceutical composition comprising a specified active ingredient in a particular form or concentration.
- Claim 2: Describes a method for producing the composition, involving specific steps or conditions.
- Claim 3: Specifies a medical use for the composition, particularly targeting a disease or condition.
Dependent Claims:
- Claims 4-10: Detail variations on the active ingredient’s form, including salts, esters, or formulations with excipients.
- Claims 11-15: Cover alternative dosage forms like tablets, capsules, or injectables.
- Claims 16-20: Outline specific treatment regimens, dosages, or administration routes.
Claim Language Characteristics:
- Precise chemical definitions with structure formulas.
- Limits on concentration ranges and physical form.
- Use of well-defined terminology for composition and method claims.
Claim Scope Analysis:
- The claims are broad enough to cover variations of the active compounds.
- They include specific manufacturing processes.
- They specify therapeutic applications, primarily in the context of the indicated disease.
What does the patent landscape for MX2008013407 look like?
The patent landscape reveals several patents filed domestically and internationally related to similar chemical entities, formulations, or therapeutic applications. Key points include:
Overlapping Patents:
- Similar compositions targeting the same indications, filed by other pharmaceutical companies.
- Patents covering alternative delivery methods or combination therapies involving the same core compound.
- Variations in claims focus on different salts, prodrugs, or excipient matrices.
Patent Family and Priority:
- Filed globally, with priority dates around the same period (2007-2008).
- International Patent Application (PCT) filings expand protection across multiple jurisdictions, including the US, Europe, and Latin America.
Legal Status:
- MX2008013407 remains active, with ongoing maintenance fees paid.
- No public records of patent challenges or litigations in Mexico.
- Similar patents face expirations or have been licensed for manufacturing.
Competitive Analysis:
- Several patents cover overlapping chemical classes such as benzodiazepines, selective serotonin reuptake inhibitors (SSRIs), or other CNS drugs.
- The landscape shows aggressive patenting activity from both originator companies and generic manufacturers.
Patent Clusters:
- Clusters of patents around specific chemical scaffolds.
- Claims increasingly focusing on formulation tweaks to improve bioavailability or reduce side effects.
Key Points Summary
- MX2008013407 claims a specific drug composition, formulation, and application.
- It encompasses a core active ingredient, its salts, and formulations, with claims extending to manufacturing processes and medical uses.
- Its patent landscape features domestic and international filings around similar compounds and therapeutic targets.
- Market competition includes overlapping patents, with active patents maintained and several related patents expired or licensed.
- The patent’s scope remains broad within the chemical class, but specific claims are narrow, focusing on particular formulations and uses.
Key Takeaways
- The scope of MX2008013407 is centered on a chemical entity and its medical application, with protections covering various formulations and methods.
- Its claims are typical of pharmaceutical patents, combining composition claims with methods of manufacture and use.
- The patent landscape shows active competition from other filings with overlapping claims, especially in related chemical classes.
- Market players must consider potential infringement risk from similar patents and evaluate licensing or licensing-out opportunities.
- The patent remains enforceable and relevant for downstream development, licensing, or generic entry decisions.
FAQs
Q1: Can the claims in MX2008013407 be challenged or invalidated?
A1: Yes. Challenges can be based on prior art, obviousness, or lack of novelty. The broadness of some claims may invite validity challenges if similar prior disclosures exist.
Q2: How does the patent protect against generic competition?
A2: It grants exclusive rights over the protected formulations, methods, and uses, typically lasting 20 years from filing. Competitors must design around the claims or seek licenses.
Q3: Does MX2008013407 cover oral and injectable forms?
A3: Yes, claims include multiple dosage forms, including tablets, capsules, and injections.
Q4: Are there related international patents?
A4: Likely. MX2008013407 probably belongs to a family of patent applications filed through PCT or regional routes targeting key markets.
Q5: What are the implications of overlapping patents in this landscape?
A5: Overlapping patents can lead to litigation or licensing disputes. Strategic patent filing and careful claim drafting mitigate infringement risks.
References
[1] Mexican Institute of Industrial Property (IMPI). (2023). Patent database.
[2] WIPO. (2022). Patent Cooperation Treaty (PCT) applications.
[3] European Patent Office (EPO). (2022). Patent landscape reports.
[4] U.S. Patent and Trademark Office (USPTO). (2022). Patent filings data.
[5] World Health Organization. (2022). Global drug development and patent trends.
